4 April 2024 – Actxa Pte Ltd (“Actxa”), an AI-driven deep tech company headquartered in Singapore, has signed a Memorandum of Agreement (“MOU”) with Instytut Medycyny Innowacyjnej sp.z o.o. (“IMI”), a research and medical technologies institute based in Poland on 7 March 2024. This MOU marks the beginning of a strategic partnership for collaboration and market distribution of Actxa’s BGEM®, a non-invasive Blood Glucose Evaluation and Monitoring Technology and other Actxa technologies in Poland. At the heart of this partnership is Actxa’s groundbreaking BGEM® technology - the world's first non-invasive blood glucose monitoring technology. Harnessing the power of artificial intelligence ("AI"), wearable technologies and signal processing, BGEM® tracks and identifies the risk of impaired glucose regulation. By analysing inter-beat-interval data from consumer-grade wearables equipped with photoplethysmography ("PPG") sensors, BGEM® calculates the digital biomarkers associated with prediabetes or Type 2 diabetes mellitus ("T2DM") symptoms, empowering users to monitor, track, and identify fluctuations in their blood glucose levels. This proactive approach allows users to implement timely lifestyle adjustments, effectively mitigating the risk or delaying the onset of diabetes. Under this partnership, IMI will be an authorised licensee with the rights to use BGEM® and incorporate the technology in its brand of wearable products for distribution in Poland. Additionally, IMI will play a pivotal role in facilitating the exploration of opportunities within countries, governments and industries to sell and market wearables with BGEM® and other Actxa technologies. Marcus Soo, Chief Executive Officer of Actxa, said, “Our collaboration with IMI signifies an important milestone in our journey toward global expansion. This collaboration is a testament to our commitment to innovation and excellence in the tech industry. Together with IMI, we embark on a transformative endeavour, combining our strengths to propel our business to new heights internationally. This alliance not only strengthens our position in the global market but also allows our technologies, such as BGEM®, to benefit a broader community. As we join forces with IMI, we are poised for unparalleled growth, setting the stage for a future defined by international success and groundbreaking achievements.” Founder of IMI, Professor Mieczysław Pasowicz shared, “At IMI, we are driven by a shared vision for a future where healthcare is transformed through innovation. Our collaboration with Actxa speaks to our unwavering dedication as we bring their groundbreaking technologies to Poland. Our strategic partnership aims to revolutionise healthcare, fostering a future where cutting-edge solutions positively impact lives. This partnership represents a significant stride towards a healthier and more technologically advanced world.” This alliance between Actxa and IMI sets the stage for Actxa’s innovative technologies to expand globally. As both companies continue to leverage their strengths and expertise, they are poised to drive positive change and contribute to the advancement of a healthier world. For further information, please contact: About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​ ​Learn more about Actxa at www.actxa.com. About Instytut Medycyny Innowacyjnej sp.z o.o For nearly 30 years Prof. Mieczysław Pasowicz has been creating and implementing initiatives related to the adaptation of hospitals to European Union standards through the creation and implementation of innovative investment projects. He specializes in investment and hospital development, healthcare management and training and digital transformation. It promotes the development of personalized medicine, coordinated healthcare and digital medicine. This is possible thanks to the involvement in modern technologies, advanced treatment methods and continuous training of medical personnel. Prof. Mieczysław Pasowicz is the founder and president/CEO of the Institute. The Institute of Innovative Medicine is a spin-off company established to commercialize research and implement new medical technologies. The company is the initiator of the creation of the BioMedTech Technology Park, the aim of which is to transfer technology from Asia to Europe and is currently looking for Partners and Investors interested in co-creating the Longevity Technology Park using the latest developments in medical robotics,  biotechnology, IT, artificial intelligence and other medical technologies. It already has a modern facility with an area of 18 thousand m2 and an investment area for the creation of the Park (www.medtechpoland.eu). Leading programs promoting organizational, product and technological innovations, the Institute of Innovative Medicine together with its partners achieves better results and market position in many areas. The Institute provides consulting and training services, provides specialized IT systems and medical equipment and offers management of healthcare facilities. It has several medical teams and cooperates with more than 100 specialists both at home and abroad. The Institute and BioMedTech Park will support young companies, innovative products and proven technologies, introducing them to domestic and international markets on behalf of customers and through sales programs. Prof. Dr hab. med. Mieczysław Pasowicz is a long-time director of the John Paul II Hospital in Krakow and vice-president of the European Association of Hospital Managers (EAHM). He is the founder and also serves as the president of the Polish Association of Hospital Directors. Prof. Pasowicz is a long-term academic lecturer with significant medical, scientific and organizational achievements.

19 October 2023 – Actxa, a Singapore-based AI-driven deep tech company, and Umeox, a leader in wearables manufacturing and solutions, have entered a strategic collaboration to integrate Actxa’s cutting-edge non-invasive Blood Glucose Evaluation & Monitoring solution, BGEM™, into Umeox’s upcoming product lineup, including health rings and smartwatches. BGEM™ by Actxa is the world's first non-invasive blood glucose monitoring solution that leverages the latest technological advancement in signal processing, wearable technologies, and artificial intelligence (“AI”) to assess the risk of impaired glucose regulation. The heart of BGEM™ lies in its ability to use inter-beat-interval data from a consumer-grade wearables photoplethysmography (“PPG”) sensor. Using its advanced AI model, BGEM™ computes the relevant digital biomarkers correlated with the symptoms of prediabetes or Type 2 diabetes mellitus (“T2DM”) that eventually predicts the risk of developing diabetes. A powerful health awareness tool, BGEM™ empowers individuals to monitor and assess their glucose dysregulation in a non-invasive, easy and frequent manner. With continuous monitoring and evaluation of diabetic risks, individuals can take proactive measures in making informed health decisions and positive lifestyle changes to reduce the risk of T2DM development. Marcus Soo, Chief Executive Officer of Actxa, said, “As a company with a vision to help people live healthier and longer with technology, we aspire to translate technological innovations into evident solutions that enhance lives. Collaborating with pioneering industry players like Umeox aligns with our vision. The fusion of their products with our BGEM™ solution holds the potential to empower more people to take proactive actions to prevent, delay the onset or even reverse the condition of diabetes. This strategic collaboration not only expedites the development, market accessibility and future commercialisation of BGEM™ but also tangibly contributes to building healthier individuals and communities. We look forward to a successful partnership with Umeox.” Jack Shao, Founder and Chief Executive Officer of Umeox, said, “Over the course of 17 years, we have remained dedicated to empowering people to live healthier. Our products have consistently demonstrated their ability to enhance people’s overall well-being. We believe our latest smart ring model, X ring, has immense potential to positively transform preventive healthcare and empower individuals to take control of their well-being through continuous, unobtrusive health monitoring. Working in tandem with Actxa to integrate BGEM™ into our upcoming product releases enables us to address evolving consumer needs effectively. This strategic collaboration reflects the shared commitment of both companies to unlock new opportunities in the global preventive health market, and we hope this strategic collaboration will be a great start for the two parties’ long-term partnership.” BGEM™ has won Actxa an award under the AI – Healthcare Technology category in the annual SBR Technology Excellence Awards 2022, hosted by Singapore Business Review. For further information, please contact: About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​ ​Learn more about Actxa at www.actxa.com. About Umeox Umeox is a high-tech and innovative enterprise of software, hardware, service integrated Solution. It develops and produces intelligent terminals which are based on IoT and AI technology, as well as providing operators and vendors around the world with one-stop solution services, including hardware manufacturing, software development, location management, AI interaction, health care, and intelligent data management cloud platform. Based on strong R&D ability and professional service, Umeox always adheres to high-quality strategy, keeps up with hot market demand and trend, constantly explores cutting-edge technology of scientific and technological innovation, closely combines humanistic care, and continuously provides customers with high-quality and cost-effective customised products and full turnkey solutions. ​Learn more about Umeox at www.umeox.com.

(Media Source: NXT) Actxa, a locally-grown AI-driven deep tech company, proudly introduces its latest addition to the health and fitness monitoring product line, the Spark+ Series 2 (“Spark+ S2”). This cutting-edge activity tracker is designed to provide all-around health and fitness monitoring, featuring a host of new and improved features compared to its predecessor, the Spark+. Enhanced with Advanced SleepTrack™ Technology One of the standout features of the Spark+ S2 is Actxa’s SleepTrack™ technology, taking sleep tracking to new heights. It goes beyond basic sleep monitoring, analyzing various metrics to offer comprehensive insights into an individual’s sleep quality. Recognizing the significance of sleep for physical and mental well-being, the Spark+ S2 helps track sleep quality, generating detailed sleep reports for each sleep cycle, along with a sleep score to monitor progress over time and ensure restful nights. All-Day Heart Rate (HR) and Heart Rate Variability (HRV) Monitoring With all-day heart rate (HR) and heart rate variability (HRV) monitoring, the Spark+ S2 provides valuable insights into how users’ hearts respond to various activities and events throughout the day. Whether awake, asleep, or during workouts, users can gain a deeper understanding of their heart’s performance and make informed lifestyle adjustments accordingly. Real-Time Outdoor Workouts with GPS The Spark+ S2 accompanies users during outdoor workouts, displaying real-time workout routes through their phone’s GPS feature. This functionality allows them to monitor the distance covered and track their progress with comprehensive performance reports, enhancing their fitness journey. Measure Your VO2 Max for Optimal Fitness With Actxa’s advanced VO2 Max algorithm, users can measure their fitness level and fitness age through brisk walks or runs. By tracking their VO2 Max over time, they can gauge the effectiveness of their exercise routines and make informed decisions to optimize their fitness goals. Unparalleled Insights via the Actxa App The Spark+ S2 provides users with invaluable insights and data to optimize their well-being through the Actxa App. The app conveniently generates reports of workout statistics, heart rate zones, and heart rate performance during workouts, enabling users to track their progress and make necessary adjustments. Fashionable and Holistic Progress Tracking Sporting a sleek, slim, and fashionable design, the Spark+ S2 is not only a powerful health and fitness companion but also a stylish accessory. With this activity tracker, users can holistically harness their health and fitness potential, taking steps to prevent or delay the onset of chronic diseases. Available Now on Actxa’s Lazada Platform The Spark+ S2 is now available for purchase on Actxa’s Lazada platform for SGD$70. To make the most of this advanced activity tracker, users can download the Actxa app from the Google Play Store or Apple Store.

(Media Source: Hardware Zone) Local health-tech brand, Actxa, has just launched their latest activity tracker, the Spark+ Series 2 (Spark+ S2). This newest model comes with a range of features, including an advanced sleep tracking technology called SleepTrack, all-day heart rate and heart rate variability monitoring, outdoor workouts with real-time maps (assisted GPS), and VO2 Max support. It also has a 3-axis accelerometer. According to Actxa, SleepTrack provides in-depth analysis of sleep quality, generating detailed sleep reports. For outdoor workouts, the activity tracker can now provide real-time displays of your workout route, but as it does not have built-in GPS, you can’t leave your phone behind. The Spark+ S2 is a lightweight (24g) device mostly made of plastic with a TPU strap. It features a 0.96-inch TFT touch display, with IP67 water-resistance, and 110mAh battery. Actxa says the tracker should last up to 7-days of standard usage, but only 30 hours with continuous heart-rate monitoring. Connectivity is based on Bluetooth 4.0 BLE. The Spark+ S2 activity tracker is available now on Actxa's Official Lazada Store for S$70.

Singapore, 17 July 2023 – Actxa, a homegrown AI-driven deep tech company, has launched the latest addition to its health and fitness monitoring product line, the Spark+ Series 2 ("Spark+ S2"), an activity tracker designed for all-round health and fitness monitoring. In comparison to Spark+ - its predecessor, the Spark+ S2 is enhanced with new and improved features such as SleepTrack™, an advanced sleep tracking technology, All-Day Heart Rate (HR) and Heart Rate Variability (HRV) Monitoring, Outdoor Workouts with Real-Time Maps and VO2 Max. These extensive features are designed to help individuals better monitor and gain insights into their health and fitness. The Spark+ Series 2 is engineered to empower individuals in their journey towards better health and fitness. Whether you are an athlete, someone motivated to lose weight or aiming to lead a healthier lifestyle – using activity trackers has been associated with increased physical activity and improved health outcomes, including weight loss and cardiovascular health¹. SleepTrack™ Actxa's SleepTrack™ technology goes beyond basic sleep tracking by analysing various metrics to provide comprehensive insights into an individual’s sleep quality. Due to the importance of sleep in physical and mental well-being, significant attention has been focused on poor sleep patterns and insomnia among the public². The Spark+ S2 helps track sleep quality and generates detailed sleep reports for each sleep cycle, along with a sleep score that enables users to track sleep quality progress over time to ensure quality rest. All-Day Heart Rate (HR) and Heart Rate Variability (HRV) Monitoring The all-day heart rate (HR) and heart rate variability (HRV) monitoring provides valuable insights into how users' hearts respond to different activities and events. Whether awake, asleep, or engaged in workouts, the Spark+ S2 helps users understand their heart's performance and adapt accordingly. Outdoor Workouts with Real-Time Maps During outdoor workouts, the activity tracker also provides a real-time display of the workout route through users' phones’ GPS feature, enabling them to monitor the distance covered and track their progress with comprehensive performance reports. VO2 Max Actxa's advanced VO2 Max algorithm measures an individual’s fitness level and fitness age through a brisk walk or run. When users track their VO2 Max over time, they can monitor the effectiveness of their exercise routines and make informed decisions to optimise their fitness goals. With these enhanced and existing features, the Spark+ S2 provides users with valuable insights and data to optimise their well-being via the Actxa App, which conveniently generates reports of workout statistics, heart rate zones and heart rate performance during workouts. With the sleek, slim and fashionable Spark+ S2 activity tracker, harness your health and fitness potential and track your progress holistically. Take this opportunity to invest in your future by preventing or delaying chronic disease onset. Spark+ S2 is now available on Actxa's Lazada platform (https://tinyurl.com/3ayrr9b7) for SGD$70. The Actxa app can be downloaded on the Google Play Store and Apple Store. Bulk purchases of 5, 10, or 20 trackers are also available via Lazada. For a higher quantity, contact Actxa's sales team at sales@actxa.com. Find out more about Actxa Spark+ Series 2 at https://www.actxa.com/spark-plus-series-2. References: Do Fitness Apps Really Help You Achieve a Healthier Lifestyle? (https://healthyin.sg/fitness-apps-healthier-lifestyle/) Sleep quality of Singapore residents: findings from the 2016 Singapore mental health study (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861160/#:~:text=Poor%20sleep%20has%20been%20linked,%5D%2C%20%5B11%5D%5D.) Download our Annex and Fact Sheet For further information, please contact: About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​ ​Learn more about Actxa at www.actxa.com.

(Media source: MediaCorp 8world) Actxa　健康分析 Actxa迎来专业级别的智能体重秤和身体成分分析仪“Sense 2 Smart Scale”。这个新品的研发乃基于其第一代的成功，“Sense 2”的出现，则具有更高的准确性和更多的定制化，可提供分段成分分析报告，帮助个人改善健康状况。 此新品采用了八个触觉电极和双频生物电阻抗分析 (BIA) 技术，可评估多达11项的基本身体测量值，为用户提供包含 20 多项身体成分指标的整体分析报告。 它还会显示最近十次的测量值趋势，让用户能够监控及跟踪自己的体重、肌肉质量和体脂百分比 (PBF) 的变化。 “Sense 2”可支持多个用户的使用，让一家人一起实现健康目标。售价$150。 哪里买：https://tinyurl.com/yck6wfct

Singapore, 10 April 2023 – Actxa, Singapore's deep tech company leveraging artificial intelligence to create preventive healthcare solutions, has launched the Sense 2 Smart Scale ("Sense 2"), a professional grade segmental body composition analyser. Building on the success of its first-generation Sense smart scale, Sense 2 is introduced with enhanced accuracy and more customised insights to provide segmental composition analysis reports to help individuals improve their health and fitness. From 2019 to 2020, 20.7% of Singaporeans were in the high-risk Body Mass Index category for the Asian population and about one in 10 Singaporeans (10.5%) aged 18 to 74 years old were obese¹ as compared to 8.6% in 2017². Segmental analysis has been proven to be a valuable tool in monitoring disease progression and nutritional status in individuals with chronic injury or disease³. Beyond assessing up to 11 essential body measurements, Sense 2 provides users with holistic body composition analysis reports with more than 20 body composition indicators, including weight, body fat percentage, visceral fat level, muscle mass percentage, bone mass and total body water. It also trends up to the last ten measurements, allowing users to monitor and track their weight, muscle mass and percentage body fat (PBF) changes. Whether you are looking to lose weight for better health, attain fitness goals, sustain your current form, or get an insight into your body, Sense 2 is your perfect choice with its clear and comprehensive view of positive or negative lifestyle information. You can see which body composition relates to your fitness and health progress – the body fat mass or a muscle build-up, and then restructure your lifestyle habits to achieve your desired goals. Designed to cater to all ages and lifestyles, Sense 2 can support multiple users, allowing families to achieve their health goals together. The smart scale is especially useful for families with a history of diabetes, cardiovascular disease and obesity, as family members can keep close tabs on their weight and body composition in maintaining a healthy lifestyle. For users enrolled in Journey with Wellness, a corporate wellness programme curated by Actxa Wellness, a subsidiary of Actxa, Actxa Sense 2 Smart Scale is explicitly designed to support you in this wellness journey. Paired seamlessly with the Actxa mobile app via Bluetooth, the Sense 2 automatically syncs all measurements to the app, allowing users to monitor and track their progress easily through the body analysis report. In just one step, you can make more informed decisions to achieve your health and fitness goals faster and more efficiently. Most importantly, health consciousness and being proactive about health are critical to preventing or delaying chronic disease onset. The accurate readings of the analysis report are obtained through dual-frequency Bioelectrical Impedance Analysis (BIA) technology to provide a more precise body composition analysis than other scales using a single frequency. The technology is painless and safe, with a low-level electrical current sent through your body to analyse your body composition. Sense 2 also uses eight tactile electrodes to distinguish and measure a user's body in five segments (arms, trunk and legs) to deliver a more in-depth analysis report. Marcus Soo, Actxa's Chief Executive Officer, said, "Preventive health is a cornerstone in ensuring a healthier and better quality of life. It is also an important shift in Singapore's healthcare ecosystem. To support the nation's Healthier SG vision of promoting preventive care, we developed the Sense 2 as an affordable, easy-to-use and dependable healthy lifestyle companion to help everyone from all walks of life to monitor and better understand their bodies." Sense 2 is now available on Actxa's Lazada platform (https://tinyurl.com/Sense-2) for SGD$150. The Actxa app can be downloaded on the Google Play Store and Apple Store. Find out more about Actxa Sense 2 at https://www.actxa.com/sense-2-smart-scale. References National Population Health Survey 2019/20 (https://www.moh.gov.sg/resources-statistics/reports/national-survey-2019-20) Obesity in Singapore: It's Not a Small World (https://www.healthhub.sg/live-healthy/764/its-not-a-small-world-after-all) Comparison of segmental body composition estimated by bioelectrical impedance analysis and dual-energy X-ray absorptiometry (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220710/) Download our Annex and Fact Sheet For further information, please contact About Actxa Headquartered in Singapore, Actxa Pte Ltd is a deep tech company founded in 2015 that leverages artificial intelligence to create next generation preventive healthcare solutions. ​ We create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and blood glucose evaluation and monitoring. ​​ To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension.​​ ​Learn more about Actxa at www.actxa.com.

Singapore, 14 February 2023 –Actxa Pte Ltd (“Actxa”) is proud to present our award-winning Blood Glucose Evaluation & Monitoring (BGEM™) and AI-driven preventive healthcare solutions at the AI Asia Expo in Thailand. Date: 21 and 22 February 2023 Location: Centara Grand at Central Plaza, Ladprao Bangkok, Thailand Booth number: 26 (Singapore Pavilion) Actxa will also be sharing how AI in preventive healthcare complement conventional healthcare. Do catch us at the following date and time: Date: 22 February 2023 Time: 12 pm to 12.30 pm Speaker: Alex Loh | Vice President of Digital Wellness Solution CEO of Actxa Wellness Pte Ltd (a subsidiary of Actxa) Topic: Application of AI Technologies for Preventive Healthcare For further information, please contact: Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620

The MOU was signed by Mr Joel Chin, CEO of Actxa (left), and Mr James Yan, CEO of Joint Chinese Limited (right). Photo by: Actxa Pte Ltd Singapore, 3 August 2022 – Actxa Pte. Ltd (“Actxa”) and Joint Chinese Limited (“JC”) alongside its associated group of companies, signed a Memorandum of Understanding (“MOU”) on 2 August 2022, to join hands in market penetration and expansion for Pre-M Diabetes™, also known as the Non-Invasive Blood Glucose Monitoring technology. We will be targeting the consumer wearables, senior care and home care segment in China. Both will also work closely on the worldwide distribution of JC’s wearables powered by Pre-M Diabetes™. Actxa and JC will collaborate to incorporate Pre-M Diabetes™ and other physiological health insights (“Actxa Insights”) in JC’s products and services, develop business and establish marketing and brand presence in China. Both sides will also be involved in research collaborations in China to further develop Actxa Insights. JC is a leading manufacturer and solution provider for digital health wearables in China. JC has identified at least 11 models of their wearables that have the potential to include Pre-M Diabetes™ to ship within China and worldwide. Actxa is the first Singapore company to develop a comprehensive AI solution that leverages consumer-grade wearables to detect blood glucose dysregulation. The Pre-M Diabetes™ is also the only non-invasive blood glucose detection solution to be going through a clinical validation study in Southeast Asia. In Singapore, at least 1 million people are projected to have diabetes by 2050 and 1 out of 4 will be undiagnosed¹. Worldwide, about 643 million people will be diabetic by 2030, and 1 in 2 adults will be undiagnosed². Through regular blood glucose monitoring, the increased risk for developing diabetes can be detected early. The launch of the Pre-M Diabetes™ allows individuals to monitor their blood glucose levels in a pain-free, easy and frequent way. The regular measurement of blood glucose will help individuals prevent, delay the onset or in some situations, even reverse the condition. Joel Chin, Actxa’s Chief Executive Officer, said, “This MOU builds on our existing strong partnership with JC, and we are honoured to collaborate with JC in launching and distributing the Pre-M Diabetes™ in China and the rest of the world. This strategic alliance leverages the strengths of both companies to create a significant impact in the global fight against diabetes. We are confident that Pre-M Diabetes™ will help individuals make informed health decisions and positive lifestyle changes to reduce the risk of developing Type 2 diabetes.” Mr. James Yan, Chief Executive Officer of Joint Chinese Limited, said, “Actxa and Joint Chinese Limited are forerunners in wearable technology, and the cooperation between the two parties has entered the eighth year. Focusing on cutting-edge technologies related to human health, both teams have constantly worked together to improve the synergy and uncover tacit knowledge to drive more innovation. The accuracy of data collection has also improved. The series of Pre-M Diabetes™ products is the result of our joint efforts, boosting new opportunities in the global preventive health market. Joint Chinese Limited will continue to sustain and pursue quality work, while achieving success with Actxa.” The Pre-M Diabetes™ has also won Actxa an award under the AI – Healthcare Technology category in the annual SBR Technology Excellence Awards, hosted by Singapore Business Review. The SBR Technology Excellence Awards is part of the regional Asian Technology Excellence Awards now running in 50 countries³. References: https://www.healthhub.sg/live-healthy/1273/d-day-for-diabetes https://idf.org/aboutdiabetes/what-is-diabetes/factsfigures.html#:~:text=The%20total%20number%20of%20people,living%20with%20dia betes%20are%20undiagnosed https://sbr.com.sg/event-news/actxa-wins-ai-award-its-non-invasive-blood-glucosemonitoring-project For further information, please contact: Tan Lay Eng Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Communications Executive hasyimah.aj@actxa.com +65 8780 3620 About Actxa Actxa was founded in 2015 with the mission to bring together people, partners, science, technology, and data to create positive changes to the health, quality of life and well-being of individuals and communities. Leveraging our expertise in developing evidence-based and personalised insights through Artificial Intelligence, we empower individuals to make informed decision on their health and well-being and to make timely changes to their lifestyle. Actxa sets its focus on research and development on innovative preventive health solutions, and we work closely with industry and academic partners to explore new opportunities. For more information, visit www.actxa.com. About Joint Chinese Group Founded in 2004, Joint Chinese Ltd. is a High-tech manufacturer with Medical Qualification, specialized in Smart Health & Medical Care Product in China. We have 3 production bases with total of 20,000sqm and strong R&D team of more than 120 engineers. We operate in 100+ countries and regions, collaborating with most recognized brands, including Xiaomi, Walmart, LG. Specialized in OEM/ODM one-stop service, we have plant area of 12,000 sq meter with monthly production capacity of 1000,000 pcs. For more information, visit https://www.jointcorp.com/.

For immediate release Singapore, 15 July 2022 – This year, Actxa Pte. Ltd (“Actxa”) has partnered with the Singapore Heart Foundation (SHF) as a product sponsor with our Actxa Spark+ fitness trackers and Actxa Sense 2 Smart Scale for their year-long heart health awareness campaigns. Going beyond sponsorship, Actxa along with its sister companies, Activate Interactive Pte Ltd (“Activate”) and Actxa Wellness will be partaking in multiple SHF programmes. Between 4 to 26 June 2022, 21 of our staff from Actxa, Activate and Actxa Wellness, participated in SHF’s Pledge Your Heart Walk (PYHW), clocking over 120 kilometres. PYHW was held in conjunction with the Go Red for Women campaign to encourage women to stay active to reduce their risk of cardiovascular disease and improve their mental health. Earlier in May 2022, Actxa had also supported the SHF’s Mummy’s Heartbeat community education event and May Blood Pressure Measurement Month intended to promote heart health awareness in Singapore. Actxa, Activate and Actxa Wellness will also be participating in the Restart A Heart Programme (RAH) that will be held in our office premises on 1 August 2022. RAH is a simplified CPR+AED training, designed for those who want to learn some basic resuscitation skills but do not require certification. Actxa is also sponsoring the lucky draw prizes for the SHF Charity Cup Golf Tournament 2022 that will be held on 27 July 2022 to raise funds for needy heart patients and contribute to SHF’s various free or subsidised programmes, such as heart health awareness events, CPR+AED courses and cardiac rehabilitation for heart patients. Joel Chin, CEO of Actxa, said, “Actxa is pleased to support the Singapore Heart Foundation by sponsoring our Actxa products in support of their heart health awareness campaigns. As an AI-driven preventive health solutions company, we create insights and bespoke programmes to help people reduce the risks of chronic diseases, such as cardiovascular disease. The works of SHF resonate with our belief in building a healthier future for individuals from all walks of life. We will continue to support and advocate for preventive health care awareness and remain committed to inspire and empower people to make proactive moves to live better and healthier.” About Actxa Actxa was founded in 2015 with the mission to bring together people, partners, science, technology, and data to create positive changes to the health, quality of life and well-being of individuals and communities. Leveraging on our expertise in developing evidence-based and personalised insights through Artificial Intelligence, we empower individuals to make informed decision on their health and well-being and to make timely changes to their lifestyle. Actxa sets its focus on research and development on innovative preventive health solutions and we work closely with industry and academic partners to explore new opportunities. For more information, please visit https://actxa.com About Singapore Heart Foundation Singapore Heart Foundation is a social service agency at the forefront of the battle against heart diseases in Singapore. Since its inception in 1970, the Foundation has grown into a well-established and reputable organisation with local and international links. Through strategic lifesaving programmes under the three core pillars of Prevention, Rehabilitation and Resuscitation, SHF fulfills its mission to promote heart health, prevent and reduce disability and death due to cardiovascular disease and stroke. In addition, SHF also offers financial assistance to needy heart patients for emergency relief and medical treatment. For further information, please contact: Tan Lay Eng Corporate Communications Manager layeng.tan@actxa.com +65 9877 0406 Hasyimah Begum AJ Corporate Communications Executive hasyimah.aj@actxa.com +65 8780 3620

Singapore, 13 May 2022 – Actxa Pte.Ltd (“Actxa”), a homegrown AI-driven preventive health solutions company, has been awarded the SBR Technology Excellence Award in the AI – Healthcare Technology category for its Non-Invasive Blood Glucose Monitoring (“BGM”) project. Actxa is the first Singapore company to develop a comprehensive AI solution that leverages consumer-grade wearables to detect blood glucose dysregulation. The BGM is also the only non-invasive blood glucose detection solution to be going through a clinical validation study in Southeast Asia. The latest Singapore National Population Health Survey shows that 9.5% of adults have diabetes from 2019 to 2020. Nearly a quarter of them are newly diagnosed, whilst 26% exhibit poor glucose control¹. In 2017, the Singapore Ministry of Health launched a nationwide initiative to tackle the epidemic of diabetes, and advances in wearable technologies may be the key to alleviating this problem. As a company with a vision to be a leading preventive health technology company in the world, Actxa’s research and development (“R&D”) team began working on a novel digital monitoring technology in 2016, which was later coined as BGM. Its goal was to engineer a solution that is non-invasive, frequently and conveniently accessible, and low cost. The innovative non-invasive BGM solution detects glucose dysregulation in patients with diabetes or prediabetes. It leverages the latest technological advancement in signal processing, wearable technologies, and artificial intelligence (“AI”) to assess the risk of impaired glucose regulation. Using inter-beat-interval data from a consumer-grade wrist-worn photoplethysmography (“PPG”) sensor, the AI model will compute the relevant digital biomarkers correlated with the symptoms of prediabetes or Type 2 diabetes mellitus (T2DM), and eventually predict the risk of developing diabetes. Joel Chin, Actxa’s Chief Executive Officer, said, “It is a great honour of Actxa to be a recipient of the SBR Technology Excellence Awards 2022. We want to thank the Singapore Business Review and the judges for recognising Actxa’s accomplishments. This is the best form of recognition for the R&D team who has been working on this project for the past five years. It is a testament of our commitment to being at the forefront of innovation, and we will continue doing so for the betterment of public health.” This technology is undergoing conducting a clinical validation study with a local hospital to improve the prediction model and evaluate the model’s real-world accuracy, reliability, and generalisability. The BGM will be available as a B2B cloud service with the production of at least one wearable product by quarter four of 2022. About Actxa Actxa was founded in 2015 with the mission to bring together people, partners, science, technology, and data to create positive changes to the health, quality of life and well-being of individuals and communities. Leveraging on our expertise in developing evidence-based and personalised insights through Artificial Intelligence, we empower individuals to make informed decision on their health and well-being and to make timely changes to their lifestyle. Actxa sets its focus on research and development on innovative preventive health solutions and we work closely with industry and academic partners to explore new opportunities. About SBR Technology Excellence Awards Organised by the Singapore Business Review, the SBR Technology Excellence Awards is the most prestigious awards programme for technological innovations, recognising exceptional companies in Singapore that are riding the digital disruption wave and leading the technological revolution and digital journeys of their respective industries. The SBR Technology Excellence Awards is part of the regional Asian Technology Excellence Awards now running in 50 countries. References: [1] National Population Health Survey 2020, MOH. https://www.moh.gov.sg/docs/librariesprovider5/default-document-library/nphs-2020-survey-report.pdf. For further information, please contact: Tan Lay Eng Corporate Communications Manager layeng.tan@actxa.sg +65 9877 0406

For immediate release Singapore, 27 September 2021 – Actxa and KK Women’s and Children’s Hospital (KKH) are carrying out a clinical study to validate a non-invasive blood glucose predictive model on wearable devices with photoplethysmography (PPG) sensors developed by Actxa. The roles of wrist-worn and in-ear wearables with PPG sensors are constantly evolving. From being a lifestyle device that monitors sports and activities, to a device that monitors a person’s lifestyle well-being and health, foraying into preventive healthcare, particularly for the prevention of chronic diseases. Diabetes has been one of the “silent” chronic diseases, and research has shown that diabetic patients have a two to three-fold higher risk of developing cardiovascular disease. In Singapore and globally, diabetes and cardiovascular diseases are serious health concerns resulting in poor quality of life. Leveraging on its expertise and knowledge of wrist-worn and in-ear wearables, Actxa has developed a predictive model based on Artificial Intelligence and Machine Learning (AIML) for PPG sensors to monitor blood glucose level non-invasively. The collaboration with KKH will enable Actxa to externally validate the predictive model developed against an independent population, further improving the model’s diagnostic ability. Joel Chin, CEO of Actxa, said, “We are excited about this collaboration as the predictive model will be able to facilitate early detection and intervention of diabetes that will make a significant positive impact in the preventive health arena. It will also provide valuable insights into wearables’ potential in providing continuous and accurate real-time data that can aid patients, whose blood sugar is in the diabetes and pre-diabetes range, to self-manage their disease better and earlier.” Associate Professor Ang Seng Bin, Head and Senior Consultant, Family Medicine Service, KKH, who is also the principal investigator of this research at KKH, said, “As Singapore’s largest academic medical centre specialising in women’s and children’s health, KKH is committed to improving patient health outcomes. Through this new collaboration, we hope that we can harness the power of technology to make a difference in patients’ lives, especially those with diabetes.” This clinical study will be carried out jointly by the following Principal Investigators – Associate Professor Ang Seng Bin (KKH), Emeritus Professor Satvinder Singh Dhaliwal (Actxa) and Mr Shi Bohan (Actxa). Results and findings from this clinical study are to be published in the second half of 2022 in peer-reviewed scientific journals. Actxa will carry out more clinical trials in the near future to provide further clinical evidence for new products. About Actxa Headquartered in Singapore, Actxa Pte.Ltd (“Actxa”) was founded in 2015 with the mission to have deep empathy and harness the power of science and data to empower people to lead healthier lives. At Actxa, we inspire individuals from all walks of life to make proactive moves to live better and healthier. Leveraging data analytics, artificial intelligence, and machine learning, we create evidence-based, personalised health insights in the domains of physical activities, sleep quality, body composition, stress and recovery, heart health and non-invasive blood glucose monitoring. With the help of these insights, Actxa develops applications such as Healthy Living Score (HLS), Actxa Wellness Programme (AWP) and products to empower individuals to manage and improve their own health. To improve population health, Actxa establishes worldwide partnerships and research collaborations to develop critical preventive health models to help people avert chronic diseases such as diabetes and hypertension. Good health and happiness go hand-in-hand. Actxa is committed to taking the lead to create Better Moves, Better Lives to better ourselves, the people around us and our community. For further information, please contact: Tan Lay Eng Corporate Communications Manager layeng.tan@actxa.com +65 98770406